meRfi®-GM
NCT00542451 - Paclitaxel + Trastuzumab & Breast Cancer / Mammacarcinoma (HER2 m)
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
A controlled phase II trial to study treating Breast Cancer / Mammacarcinoma (HER2+) women with Paclitaxel + Trastuzumab
Primary outcome measures:
3-year Disease Free Survival (DFS) Rate
The authors concluded that adjuvant paclitaxel and trastuzumab are associated with excellent long-term outcomes with longer follow-ups. The distribution of PAM50 intrinsic subtypes in small HER2-positive tumors is similar to that previously reported for larger tumors.
Tolaney et al. 2019
…